Business

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., February 11, 2026--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2025 financial results before the market opens on Wednesday, February 25, 2026. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time.

articleUnited Therapeutics CorporationFebruary 11, 20262/company/united-therapeutics-corporation/news/united-therapeutics-corporation-report-fourth-120000987
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026

About this update from United Therapeutics Corporation

[{"type":"text","content":"SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., February 11, 2026--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2025 financial results before the market opens on Wednesday, February 25, 2026. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time.","length":399,"tagName":"p"},{"type":"text","content":"United Therapeutics will host a public webcast Wednesday, February 25, 2026, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics’ website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location.","length":321,"tagName":"p"},{"type":"text","content":"United Therapeutics: Enabling Inspiration","length":41,"tagName":"p"},{"type":"text","content":"At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.","length":592,"tagName":"p"},{"type":"text","content":"You can learn more about what it means to be a PBC here: unither.com/pbc.","length":73,"tagName":"p"},{"type":"text","content":"Forward-Looking Statements","length":26,"tagName":"p"},{"type":"text","content":"Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertaintie...

More updates from United Therapeutics Corporation

United Therapeuticspublic benefit corporationpublic benefitForward-Looking Statementspharmaceutical therapiesPrivate Securities Litigation Reform Act of 1995